Flatiron Health is spotlighting its expanding oncology data and AI capabilities this week as it ramps up activity around the ASCO 2026 conference. The company reported that its real-world data underpins more than 25 accepted abstracts, including 14 Flatiron-authored posters, reinforcing its role in evidence generation across multiple tumor types.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
A major focus is the introduction of Flatiron Telescope, an AI-powered oncology intelligence platform built on over 15 years of longitudinal real-world data from more than 5 million patient journeys across the U.S., U.K., Germany, and Japan. Telescope is designed to let life sciences teams create cohorts via natural language, assess feasibility in real time, and run on-demand treatment pattern and outcomes analyses.
Flatiron plans live Telescope demonstrations and broader platform showcases at ASCO Booth #21149, alongside networking events aimed at biopharma and clinical stakeholders. The company is also promoting oncology research that leverages its LLM-enabled NSCLC Panoramic dataset, covering use cases such as digital twin model validation and analyses linking survival and treatment response to metastatic site clusters.
Additional work centers on real-world evidence in harder-to-study areas, including platinum-resistant ovarian cancer using a Panoramic dataset of more than 30,000 patients. Studies presented at ASCO explore platinum re-challenge patterns and outcomes, potentially informing treatment decisions where randomized trial data are limited and highlighting the value of Flatiron’s granular longitudinal data.
Flatiron is emphasizing evidence partnerships with academic medical centers and health systems, including collaborations examining optimal immunotherapy duration around the two-year mark. These initiatives, featured at conferences like REDigitalHealth, are positioned as mechanisms to speed research cycles, empower clinicians, and integrate real-world insights back into routine oncology practice.
Survey data cited by Flatiron from work with Life Science Strategy Group and Deloitte indicate that 89% of nearly 200 biopharma decision-makers rank data quality and completeness as a top priority, with 45% naming it the main barrier to predictive modeling. According to the company, 75% of respondents perceive Flatiron as outperforming competitors on these metrics, particularly in oncology.
The surveys link high-quality real-world datasets to the effectiveness of emerging AI applications, suggesting that robust data foundations are increasingly seen as critical to regulatory submissions and advanced analytics. Flatiron is using these findings to underscore its positioning as a “gold standard” in oncology intelligence and to differentiate its infrastructure from smaller or less specialized RWE vendors.
Taken together, the week’s developments highlight Flatiron’s push to combine broad conference visibility, new AI-driven products, and perceived leadership in data quality. While commercial outcomes are not yet disclosed, these moves appear aimed at deepening biopharma and provider adoption, supporting long-term demand for oncology-focused real-world evidence and analytics solutions.